UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 713, 2025

Serina Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

1-38519

82-1436829

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

601 Genome Way, Suite 2001

Huntsville, Alabama 35806

(Address of principal executive offices)

(256) 327-9630

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock, par value $0.0001 per share

SER

NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ~~Emerging growth company o~~

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 52.0702 ~~Submission~~Results of ~~Matters~~Operations toand aFinancial ~~Vote of Security Holders.~~Condition

~~The~~On ~~Board~~November 13, of2025, ~~Directors of~~ Serina Therapeutics, Inc. ~~(the~~issued ~~“Company”)~~a ~~held~~press ~~the~~release ~~Company’s~~announcing ~~2025~~its ~~Annual~~financial ~~Meeting~~results offor the ~~Stockholders~~quarter ~~(the~~ended ~~“Annual Meeting”) on November 7~~September 30, 2025. A ~~quorum~~copy ~~was~~of ~~present at~~ the ~~meeting.~~press ~~The~~release ~~final~~is ~~results~~furnished ofas ~~voting~~Exhibit ~~for~~99.1 ~~each matter submitted to a vote of stockholders at the Annual Meeting are set forth below~~hereto.

~~Proposal~~The information in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Election of Two Directors

Voting results for the election of directors were as follows:

Nominees	For	Withheld	Broker Non-Votes
Steve Ledger	4,165,885	93,287	2,681,141
Karen J. Wilson	4,169,893	89,279	2,681,141

Accordingly, both of the Company’s nominees were elected to serve as directors of the Company until the 2028 Annual Meeting of Stockholders or until their respective successors are appointed, elected and qualified.

Proposal 2

Ratification of the Appointment of Auditors

Ratification of the appointment of Frazier & Deeter, LLC as the Company’s independent registered public accounting firm for the 2025 fiscal year was approved by the following vote:

For			Against			Abstain			Broker Non-Votes
6,544,850			377,827			17,636			—

Proposal 3

Approval of the Convertible Note and Warrants Proposal

As described in the Company’s Proxy Statement, the issuance of common stock in connection with the exercise of the Convertible Note and Warrants was approved by the following vote:

For			Against			Abstain			Broker Non-Votes
4,149,038			108,481			1,653			2,681,141

Item 9.01 - Financial Statements and Exhibits.

(d) Exhibits


Exhibit Number						Description

99.1						Press Release of Serina Therapeutics, Inc. issued on November 13, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

ExhibitNumber						Description
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SERINA THERAPEUTICS, INC.
Date: November 12, 2025	By:	/s/ Steve Ledger
Date: November 13, 2025	By:	/s/ Steve Ledger
		Chief Executive Officer

Filing Compare · Serina Therapeutics, Inc.